1 Day
Source:
اقتصاد سكاي نيوز عربية
GSK acquires Novanent for $10.6B
British pharmaceutical company GSK announced its acquisition of American Novartis for $10.6 billion in a deal that strengthens its presence in the cancer treatment sector and the U.S. market. The deal includes three lung cancer drugs still in clinical trial phases, which are expected to be launched in the market later this year after regulatory approvals. This move comes as part of the company's efforts to expand its investments in the cancer drug market, despite industry challenges posed by tariffs and economic disruptions.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)